What is the recommended duration of rituximab treatment for neuromyelitis optica?

No direct evidence for the optimal duration of rituximab in neuromyelitis optica exists; indirect evidence suggests a practice of continuous treatment for at least five years, adapted based on patient-specific B-cell monitoring.

Authors

Tripdatabase

Publication Details

Journal: Zenodo (CERN European Organization for Nuclear Research)
Published: 2026-11-07
DOI: https://doi.org/10.5281/zenodo.24040000
Primary Topic: Multiple Sclerosis Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

NOV

article

What is the recommended duration of rituximab treatment for neuromyelitis optica?

Tripdatabase

Nov 7, 2026

Zenodo (CERN European Organization for Nuclear Research)

Multiple Sclerosis Research Studies

article

What is the recommended duration of rituximab treatment for neuromyelitis optica?

Tripdatabase

November 7, 2026article en

Abstract

Zenodo (CERN European Organization for Nuclear Research)

Good health and well-being

Openalex Percentile: Top 15%

Multiple Sclerosis Research Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon

What is the recommended duration of rituximab treatment for neuromyelitis optica? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS